Enzalutamide

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
December, 2024
December 2024
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  

Enzalutamide
Nov 3, 2024, 09:32 | Blog
Sabine D. Brookman-May: ESSA terminates Phase 2 trial
Sabine D. Brookman-May posted on X: "ESSA terminates Phase 2 trial: masofaniten (Epi-7386/N-terminal AR antagonist)…
Oct 14, 2024, 15:14 | Drugs
Toni Choueiri: Talazoparib with or without enzalutamide in mCRPC
Toni Choueiri shared on X: ''JUST IN: HUGE NEWS ==> OS benefit from TALAPRO-2 study…
Sep 26, 2024, 12:37 | Insight
Exclusive Interview With Fred Saad
MediaMedic shared on LinkedIn: “Exclusive Insights on mHSPC Treatment: Interview with Fred Saad. In a…
Sep 22, 2024, 12:38 | Blog
Amol Akhade: Cabozantinib plus Atezolizumab vs second-line NHT in prostate cancer
Amol Akhade shared a post on LinkedIn: ''Cabozantinib plus Atezolizumab versus second-line Non-hormonal Therapy (NHT)…
Sep 18, 2024, 11:25 | Insight
Toni Choueiri: PEACE-3 phase 3 trials first results at ESMO24
Katy Beckermann, Assistant Professor Of Medicine, Vanderbilt University Medical Center, shared a post on X by…
Sep 17, 2024, 15:12 | Blog
Oriol Mirallas: PEACE-3 - Enzalutamide + Radium-223 vs Enzalutamide alone
Oriol Mirallas shared a post on X: ''Presidential Session at ESMO. PEACE-3: Enzalutamide (Enza) +…
Sep 14, 2024, 14:59 | Insight
Keeping up with Day 1 ESMO24 with Yüksel Ürün
The ESMO Congress 2024 (ESMO24) is taking place from 13-17 September 2024, in Barcelona. ESMO24…
Sep 12, 2024, 09:57 | Insight
Meta-analysis of 20 RCTs with 14,995 Metastatic Castrate-sensitive Prostate Cancer patients
Emre Yekedüz, Associate Professor of Medical Oncology at Ankara University and Research Fellow at Dana-Farber Cancer Institute, shared…
Aug 23, 2024, 14:37 | Insight
Yüksel Ürün: Enzalutamide boosts OS and rPFS in mHSPC patients regardless of HSD3B1 genotype
Yüksel Ürün shared a paper by Nima Sharifi et al. on X: "Enzalutamide boosts OS…
Aug 21, 2024, 16:16 | Blog
How to address anticoagulation during cancer therapies - International Cardio-Oncology Society
Avirup Guha, Director of cardio oncology at Georgia Cancer Center shared a post on X…
Aug 1, 2024, 04:07 | Blog
EORTC-1333-GUCG/PEACE III trial has reached it's primary endpoint
María Natalia Gandur Quiroga shared a post on X: "Exciting news from EORTC!  EORTC-1333-GUCG/PEACE III…
Jul 11, 2024, 12:34 | Insight
Ravi Madan: Enzalutamide Monotherapy in the EMBARK Trial Should Be Practice-changing
Ravi Madan, Clinical researcher focused on Prostate Cancer at National Cancer Institute, shared a post…
Jun 24, 2024, 01:07 | Blog
Yüksel Ürün: Our comment about 'Cardiovascular Events and Androgen Receptor Signaling Inhibitors in Advanced Prostate Cancer'
Yüksel Ürün shared on X: "Our comment about 'Cardiovascular Events and Androgen Receptor Signaling Inhibitors in…
Jun 6, 2024, 10:53 | Insight
Earle Burgess: The best part of the oral prostate cancer session at ASCO24
Earle Burgess, Genitourinary Medical Oncologist, Atrium Health Levine Cancer Institute, shared a post on LinkedIn: “What…
Jun 4, 2024, 04:53 | Insight
Earle Burgess: Fascinating preliminary phase I trial data in mCRPC at ASCO24
Earle Burgess, Genitourinary Medical Oncologist at Atrium Health Levine Cancer Institute, shared a post on LinkedIn:…
Apr 19, 2024, 20:03 | Insight
Piotr Wysocki: BRCA1/2 mutations represent a poor prognostic factor for mCRCP patients - underscoring the need to use PARPi as soon as possible
Piotr Wysocki, Professor of Medicine and Head of the Department of Oncology at Jagiellonian University…
Apr 15, 2024, 16:45 | Drugs
NCCN 2024 Prostate Cancer Guidelines Update by Maria Natalia Gandur Quiroga
Maria Natalia Gandur Quiroga shared a post on X: “NCCN 2024 Prostate Cancer Guidelines Update.…
Apr 15, 2024, 14:41 | Drugs
Piotr Wysocki: The [177Lu]Lu-PSMA-617 plus enzalutamide combination is active and safe in mCRPC patients, but is it really an option for first-line treatment?
Piotr Wysocki, Professor of Medicine and Head of the Department of Oncology at Jagiellonian University…
Mar 15, 2024, 18:07 | Insight
Talazoparib in Combination With Enzalutamide for Prostate Cancer - FDA Oncology
FDA Oncology posted on X/Twitter: "FDA Approval Summary: Talazoparib in Combination With Enzalutamide for Treatment…
Jan 31, 2024, 18:28 | Drugs
Day 1 of GU24 ASCO Highlights by Oncology Brothers
Oncology Brothers shared on their X/Twitter page: "Day 1 GU24 ASCO Highlights 1. CONTAC02: Atezo/Cabo…
Dec 6, 2023, 13:54 | Insight
Yüksel Ürün: The TALAPRO-2 trial shows a promising combo of talazoparib and enzalutamide for metastatic castration-resistant prostate cancer with HRR gene alterations
Yüksel Ürüna, Professor at Ankara University School of Medicine, shared on X/Twitter: "The TALAPRO-2 trial shows…
Nov 21, 2023, 14:18 | Drugs
5 new drug indications by FDA Oncology in the last 10 days - Oncology Brothers
Quoting Oncology Brothers on X/Twitter: "What just happened? 5 new drug indications by FDA Oncology…
Nov 19, 2023, 16:51 | Drugs
Karine Tawagi: New U.S. FDA approval for Enzalutamide in BCR prostate cancer
Karine Tawagi, Assistant Professor of Clinical Medicine and Associate Program Director at the University of…
Aug 25, 2023, 18:22 | Insight
Earle Burgess: Which newly diagnosed metastatic castrate-sensitive prostate cancer patients need to add docetaxel chemotherapy to an ADT + ARPI doublet?
Quoting Earle Burgess, Genitourinary Medical Oncologist and Clinical Researcher at Atrium Health, Levine Cancer Institute,…
Jun 21, 2023, 18:41 | Drugs
So pleased (& a little proud) to see U.S. FDA approval of Enzalutamide & Talazoparib in HRR-deficient 1L mCRPC
In a post by Arun Azad on Twitter, it says, "So pleased (& a little…
All: 25 Posts: 1 - 100
Special Coverage